CDx Diagnostics, Inc. today announced that it has received its 400,000th WATS3D specimen. WATS3D, the company’s proprietary diagnostic platform leverages AI enabled tissue analysis and 3D imaging to identify precancerous cells in the esophagus. This remarkable achievement speaks to the company’s commitment to changing the landscape of cancer prevention through innovative technological solutions.



Esophageal cancer, a deadly disease with a mere 20% five-year survival rate, has seen a staggering 767% increase in incidence in the US over the past 40 years. During that time, the Seattle protocol, relying on random four-quadrant forceps biopsies, served as the standard technique for detection of Barrett’s esophagus (BE) and dysplasia. This approach has proven inadequate, with high sampling error rates that contribute to approximately 50% miss rate of BE cases during patients' screening upper endoscopies, underscoring the need for improved diagnostic approaches. Barrett’s esophagus is the sole known precursor to this cancer.


The WATS3D 3-in-1 solution is well documented to find Barrett’s esophagus and dysplasia more reliably than the current standard alone. When added as an adjunct to random forceps biopsy, WATS3D has been shown to be effective at increasing the detection of BE and dysplasia by 153% and 242%, respectively, for patients with no prior diagnosis of Barrett’s and those in surveillance. Additionally, studies have demonstrated that WATS3D increases diagnostic yield regardless of Barrett’s segment length.


“As an author of many of the WATS3D-related publications in the peer-reviewed literature, which represent over 20,000 procedures, it is clear that this technology provides an opportunity to identify more cancer and pre-cancer compared to the current practice of using only forceps biopsies. The data clearly show a benefit of adjunctive use of the WATS3D device and AI system throughout the Barrett's esophagus life cycle, from initial diagnosis to surveillance before and after endoscopic eradication therapy,” said Dr. Michael S. Smith, Chief of Gastroenterology & Hepatology, Mount Sinai West & Mount Sinai Morningside Hospitals. Dr. Smith is a paid consultant with CDx Diagnostics. He has not received compensation for his work on the WATS3D studies or this press release.
https://www.cdxdiagnostics.com/news/wats3d-procedures-marks-significant-milestone